| Bioactivity | CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy[1]. |
| Invitro | CXJ-2 (10 μM , 24 h) 以剂量依赖性方式降低 LX2 细胞中的 α-SMA 表达[1]。CXJ-2 (10 μM , 24 h) 表现出优异的抑制 LX2 细胞增殖的活性[1]。 |
| In Vivo | CXJ-2 (150 μg/kg，腹腔注射，每日一次，持续 3 周)可显著减轻小鼠肝纤维化[1]。CXJ-2 (0.1 mg/kg，皮下注射，单剂量)显示出良好的药代动力学特性[1]。 Animal Model: |
| Name | CXJ-2 |
| Sequence | cyclo(Val-{Iva}-Gly-Ser-Pro-Ser-Ala-Gln-Glu-Glu-Ala-Ser-Pro-Ala) |
| Shortening | cyclo(V-{Iva}-GSPSAQEEASPA) |
| Formula | C55H87N15O22 |
| Molar Mass | 1310.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Song N, et al. Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis. J Med Chem. 2023 Apr 13;66(7):4689-4702. |